Regulation of metformin response by breast cancer associated gene 2

Neoplasia (United States)

Volumn 15, Issue 12, 2013, Pages 1379-1390

  Buac, Daniela ^a   Kona, Fathima R ^a   Seth, Arun K ^b   Ping Dou, Q ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; METFORMIN; RING FINGER PROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER ASSOCIATED GENE 2; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DENSITOMETRY; GENE; GENE OVEREXPRESSION; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; UBIQUITINATION; WESTERN BLOTTING;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; METFORMIN; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEOTIDES; UBIQUITIN-PROTEIN LIGASES;

EID: 84891601317     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131434     Document Type: Article

References (47)

1. Ciechanover A, Orian A, and Schwartz AL (2000). The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J Cell Biochem Suppl 34, 40-51.
2. Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, and Dou QP (2013). From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des 19, 4025-4038.
3. Chen D and Dou QP (2010). The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci 11, 459-470.
4. Nalepa G and Wade Harper J (2003). Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 29(suppl 1), 49-57.
5. Burger A, Amemiya Y, Kitching R, and Seth AK (2006). Novel RING E3 ubiquitin ligases in breast cancer. Neoplasia 8, 689-695.
6. Burger AM, Gao Y, Amemiya Y, Kahn HJ, Kitching R, Yang Y, Sun P, Narod SA, Hanna WM, and Seth AK (2005). A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 65, 10401-10412.
7. Kona FR, Stark K, Bisoski L, Buac D, Cui Q, and Dou QP (2012). Transcriptional activation of breast cancer-associated gene 2 by estrogen receptor. Breast Cancer Res Treat 135, 495-503.
8. Bacopulos S, Amemiya Y, Yang W, Zubovits J, Burger A, Yaffe M, and Seth AK (2012). Effects of partner proteins on BCA2 RING ligase activity. BMC Cancer 12, 63.
9. Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M, Guatelli J, and Yamamoto N (2009). BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 5, e1000700.
10. Nelson DL, Lehninger AL, and Cox MM (2008). Lehninger Principles of Biochemistry. W.H. Freeman, New York.
11. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, and Hardie DG (1996). Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271, 27879-27887.
12. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, and Hardie DG (2003). Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2, 28.
13. Carling D and Hardie DG (1989). The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1012, 81-86.
14. American Diabetes Association (2009). Standards of medical care in diabetes- 2009. Diabetes Care 32(suppl 1), S13-S61.
15. Pollak MN (2012). Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2, 778-790.
16. Dowling RJ, Niraula S, Stambolic V, and Goodwin PJ (2012). Metformin in cancer: translational challenges. J Mol Endocrinol 48, R31-R43.
17. Amemiya Y, Azmi P, and Seth A (2008). Autoubiquitination of BCA2 RING E3 ligase regulates its own stability and affects cell migration. Mol Cancer Res 6, 1385-1396.
18. Davies SP, Sim AT, and Hardie DG (1990). Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem 187, 183-190.
19. Corton JM, Gillespie JG, Hawley SA, and Hardie DG (1995). 5-Aminoimidazole- 4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229, 558-565.
20. Burger AM, Kona F, Amemiya Y, Gao Y, Bacopulos S, and Seth AK (2010). Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer. Open Cancer J 3, 116-123.
21. Carling D, Thornton C, Woods A, and Sanders MJ (2012). AMP-activated protein kinase: new regulation, new roles? Biochem J 445, 11-27.
22. Zungu M, Schisler JC, Essop MF, McCudden C, Patterson C, and Willis MS (2011). Regulation of AMPK by the ubiquitin proteasome system. Am J Pathol 178, 4-11.
23. Qi J, Gong J, Zhao T, Zhao J, Lam P, Ye J, Li JZ, Wu J, Zhou HM, and Li P (2008). Downregulation of AMP-activated protein kinase by Cideamediated ubiquitination and degradation in brown adipose tissue. EMBO J 27, 1537-1548.
24. Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, and Alessi DR (2008). Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33- linked polyubiquitin chains. Biochem J 411, 249-260.
25. Witczak CA, Sharoff CG, and Goodyear LJ (2008). AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. Cell Mol Life Sci 65, 3737-3755.
26. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, and Morris AD (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305.
27. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, McDougall G, Wang HH, Xue L, Jiang H, et al. (2012). Cellular responses to the metal-binding properties of metformin. Diabetes 61, 1423-1433.
28. Owen MR, Doran E, and Halestrap AP (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(pt 3), 607-614.
29. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, et al. (2008). Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414-1418.
30. Shackelford DB and Shaw RJ (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9, 563-575.
31. Jeon SM, Chandel NS, and Hay N (2012). AMPK regulates NADPHhomeostasis to promote tumour cell survival during energy stress. Nature 485, 661-665.
32. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al. (2009). AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8, 733-741.
33. Vazquez-Martin A, Oliveras-Ferraros C, and Menendez JA (2009). The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle 8, 2385-2398.
34. Ríos M, Foretz M, Viollet B, Prieto A, Fraga M, Costoya JA, and Señarís R (2013). AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res 73, 2628-2638.
35. Phoenix KN, Vumbaca F, and Claffey KP (2009). Therapeutic metformin/ AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113, 101-111.
36. Zakikhani M, Blouin MJ, Piura E, and Pollak MN (2010). Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123, 271-279.
37. Kuznetsov JN, Leclerc GJ, Leclerc GM, and Barredo JC (2011). AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther 10, 437-447.
38. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, and Barredo JC (2007). Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β- 4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 6, 46.
39. Leclerc GM, Leclerc GJ, Fu G, and Barredo JC (2010). AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. J Mol Signal 5, 15.
40. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, and Luo Z (2010). AMPK exerts dual regulatory effects on the PI3K pathway. J Mol Signal 5, 1.
41. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, and Gandini S (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3, 1451-1461.
42. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, and Fantus IG (2008). Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8, 501-505.
43. Campagnoli C, Pasanisi P, Abbà C, Ambroggio S, Biglia N, Brucato T, Colombero R, Danese S, Donadio M, Venturelli E, et al. (2012). Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 12, 175-182.
44. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, et al. (2011). Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128, 783-794.
45. Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467.
46. Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2, 205-213.
47. Dent S, Oyan B, Honig A, Mano M, and Howell S (2013). HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev 39, 622-631.